FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy

Oct. 03, 2022 5:33 PM ETOncternal Therapeutics, Inc. (ONCT)By: Anuron Mitra, SA News Editor1 Comment

Non-Hodgkin Lymphoma (NHL)

jarun011/iStock via Getty Images

  • Clinical-stage biopharma Oncternal Therapeutics (NASDAQ:ONCT) on Monday said the U.S. FDA had cleared it to proceed with a phase 1/2 dose escalation study of its car T-cell therapy ONCT-808 for the treatment of aggressive B

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.